Hemophilia B mice given BEQVEZ: liver hFIX-R338L expression and hemostatic FIX activity
“Mice with a hemophilia B phenotype that were administered BEQVEZ at the recommended clinical dose level expressed the hFIX-R338L transgene in the liver and exhibited hemostatic FIX activity, supporting the expected activity and mechanism of action of the product.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Why that model
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reviewer's view of the efficacy data
FDA judged canine-FIX surrogate data in dogs expected to be representative of BEQVEZ
“Animals in this study were administered an AAVRh74var vector encoding the canine factor IX gene. However, safety and activity data resulting from administration of this surrogate would be expected to be representative of BEQVEZ.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function